YvetteLeslieKasamonMD

Hematologic Oncology

Physician, Division of Hematologic Malignancies II, Office of Oncologic Diseases, FDA and Adjunct Associate Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Kasamon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kasamon's full profile

Already have an account?

Office
FDA, 10933 New Hampshire Ave
White Oak 22/ 2163
Silver Spring, MD 20903
Phone+1 240-402-3694

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Pittsburgh School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2002 - 2026
American Board of Internal Medicine Hematology

Clinical Trials

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 1, Phase 2
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2006 Aug 01
Withdrawn
Phase 2
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies Start of enrollment: 2006 Oct 01
Terminated
Phase 1
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma Start of enrollment: 2006 May 01
Completed
Phase 2
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma Start of enrollment: 2007 Apr 01
Terminated
Phase 1, Phase 2
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab Start of enrollment: 2009 Jul 01
Terminated
Phase 2
124I-FIAU Imaging in EBV and KSHV Associated Cancers Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Start of enrollment: 2010 Sep 01
Recruiting
Phase 1, Phase 2
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Start of enrollment: 2011 Aug 01
Completed
Phase 1
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.
Maryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, Lisa R Rodriguez, Susan Jin
Clinical Cancer Research. 2024-12-16
3 citations
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million Tegenge
Clinical Cancer Research. 2024-06-03
4 citations
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Deepti Telaraja, Yvette L Kasamon, Justin S Collazo, Ruby Leong, Kun Wang
Clinical Cancer Research. 2024-01-05

Journal Articles

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF., Blood, 2/16/2012

Abstracts/Posters

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)
Yvette L. Kasamon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures